Stay updated with breaking news from Michael castagna. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MannKind (MNKD) Granted Parent for New Clofazimine Formulation streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Danbury-headquartered MannKind Corp. announced the U.S. Patent and Trademark Office issued a new patent (No. 11,793,808) covering the company’s clofazimine inhalation suspension (MNKD-101), which is under development for the potential treatment of nontuberculous mycobacterial (NTM) lung disease. ....
Wedbush initiated coverage on shares of MannKind (NASDAQ:MNKD – Free Report) in a research report released on Monday morning, MarketBeat reports. The firm issued an outperform rating on the biopharmaceutical company’s stock. Wedbush also issued estimates for MannKind’s Q3 2023 earnings at ($0.02) EPS, Q4 2023 earnings at ($0.03) EPS, FY2023 earnings at ($0.10) EPS, […] ....
MannKind Co. (NASDAQ:MNKD – Get Free Report) CEO Michael Castagna sold 10,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $4.61, for a total transaction of $46,100.00. Following the sale, the chief executive officer now directly owns 2,436,039 shares of the […] ....